Psychedelic Mushrooms Products Market in US Size to grow by USD 343.73 million between 2024-2028

According to a research report “ Psychedelic Mushrooms Products Market in US” by Product (Psilocybe, Gymnopilus, Panaeolus) Type (Dried, Fresh/whole, Processed) Application (De-addiction, Recreational, Therapeutic) Geography (North America)- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 343.73 million, at a CAGR of  10.05% during the forecast period. The psychedelic mushroom products market in the US is experiencing significant growth due to shifting societal attitudes and increased acceptance of psychedelic substances. This trend is driven by a combination of factors, including changing cultural norms, a better understanding of the therapeutic benefits of psychedelics, and a growing interest in holistic approaches to mental health and well-being. Decriminalization efforts and ballot measures across the country reflect this shift in public opinion. Media coverage, such as documentaries and books, have further shaped a favorable narrative around psychedelic mushrooms, highlighting their potential medicinal benefits and role as a tool for self-discovery. As more individuals seek alternative methods for improving their mental and emotional well-being, the demand for psychedelic mushroom products is expected to continue rising.

Browse market data tables, figures, and in-depth TOC on “Psychedelic Mushrooms Products Market in US” by Product (Psilocybe, Gymnopilus, Panaeolus) Type (Dried, Fresh/whole, Processed) Application (De-addiction, Recreational, Therapeutic) Geography (North America) Global Forecast to 2028. Download Free Sample

By Product, the Psilocybe segment is projected to dominate the market size in 2024

The psychedelic mushrooms market in the US is experiencing significant growth, with dried types emerging as a preferred choice among consumers. Driven by convenience, longer shelf life, and ease of storage, dried mushrooms are gaining popularity over fresh alternatives. The demand for psychedelic mushroom products is fueled by diverse applications, encompassing both recreational and therapeutic use. Consumers value the adaptability of dried mushrooms, which can be incorporated into various intake methods such as teas, capsules, or foods. The rise of microdosing trends and the convenience of precise dosage with dried forms are further catalyzing market expansion.

By Type, Dried  segment is expected to hold the largest market size for the year 2024

The business landscape for Psilocybe, a distinguished genus of psychedelic mushroom products, in the US psychedelic mushroom market is favorable. Psilocybe species, renowned for their psychoactive compound psilocybin, are garnering attention for their potential therapeutic and recreational applications. Societal acceptance and evolving legal frameworks create an auspicious environment for Psilocybe product expansion. The burgeoning curiosity towards natural psychedelics in the US, coupled with ongoing research into their medicinal benefits, fuels market growth. Despite regulatory hurdles, the demand for Psilocybe mushroom products is anticipated to be propelled by their unique qualities and potential contributions to mental health and personal well-being.

North America is forecasted to hold the largest market size by region in 2024

ai_geographic_landscape

The Psychedelic Mushrooms Products Market in US growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

• ATAI Life Sciences N.V
• Blissmushrooms
• Compass Pathways plc 
• Galaxy treats
• Psychedelic Mushy

For insights on company offerings- Request a sample report!

Research Analysis Overview

The psychedelic mushrooms market in the US is gaining momentum as scientific research explores their therapeutic benefits for various mental health conditions. Dried psilocybin-containing mushrooms, a popular form of these psychoactive substances, have shown promise in psychotherapy for conditions such as hopelessness, mood disorders, and end-of-life anxiety. Companies like Compass Pathways are leading the charge, developing psilocybin therapy for treatment-resistant depression and PTSD. Despite the growing body of scientific evidence supporting the efficacy and safety of these substances, attitudes towards psychedelics remain complex. Advocacy groups are pushing for decriminalization and destigmatization, while enforcement agencies continue to view possession as a crime. Brain activity during psilocybin sessions reveals unique patterns, suggesting potential applications in personality and behavior modification. However, more research is needed to fully understand the therapeutic potential of these substances and their long-term safety implications. Psilocybin has shown promise in treating addiction, anxiety, depression, and PTSD. Scientific research is ongoing, and early results are encouraging. As the psychedelic renaissance continues to unfold, it's essential to keep an open mind about the therapeutic benefits of these substances while ensuring safety and ethical use.

Market Research Overview

The psychedelic mushrooms products market in the US has seen a surge in growth, particularly in the online retail sector. Brands like Marley One, Silo Wellness, Psychedelic Mushroom Co., oneupmushroomsbar.com, Blissmushrooms, Galaxy Treats, Shroomland, and others offer a range of psychedelic mushroom tinctures, gummies, and functional mushroom tinctures. These products cater to both recreational and therapeutic segments. Psychedelic mushrooms, also known as plant-based entheogens, have been used for centuries for their therapeutic benefits. However, they come with side effects such as loss of coordination and vomiting. The high cost and potential for negative experiences have kept them out of reach for many, particularly low-income communities. Advocacy groups are pushing for the decriminalization of psychedelics for therapeutic applications, including substance abuse, addiction to nicotine and alcohol, PTSD, anxiety, depression, and end-of-life anxiety. Scientific research is showing the efficacy and safety of psychedelics in healthcare settings, and companies like Compass Pathways are leading the way in developing psilocybin-based therapies. Despite the potential benefits, attitudes towards psychedelics remain divided. Possession and enforcement remain contentious issues, with some arguing that these substances have therapeutic potential and others warning of the risks. As the movement gains momentum, it will be important to balance the therapeutic benefits with safety and regulatory considerations. Creativity, euphoria, and mood enhancement are among the reported therapeutic benefits of psychedelics. Dried mushrooms, gellies, gums, and tinctures offer convenient and discreet options for consumers on the internet. However, it's important to remember that these substances can have side effects and should be used responsibly.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/